Literature DB >> 16555109

Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver.

Abdurrahman Karaman1, Ersin Fadillioglu, Emine Turkmen, Erkan Tas, Zumrut Yilmaz.   

Abstract

Hepatic ischemia-reperfusion (I/R) injury may be developed in some conditions, such as trauma, major hepatic resection, hemorrhagic shock or liver transplantation. I/R injury of the liver causes hepatocellular damage that may lead to hepatic failure. A considerable body of evidence indicates that reactive oxygen species (ROS) and inflammation may contribute to hepatocellular injury in liver I/R. Leflunomide is an isoxazole derivative, and a unique immunomodulatory agent. In the present study, we examined the effects of leflunomide on the neutrophil activation with oxidative stress and some antioxidant enzymes in the reperfusion following I/R in the rat liver. Thirty-two rats divided into four groups: group 1 (control); was given leflunomide 10 mg/kg, i.g.; group 2 (SHAM), animals were only laparotomized; group 3 (liver I/R), and group 4 (liver I/R + Leflunomide). In group 4, rats were pretreated with leflunomide (10 mg/kg, i.g.) two doses prior to experiment. In groups 3 and 4, occluding the hepatic pedicel for 60 min induced ischemia and reperfusion was allowed thereafter for 60 min. At the end of the reperfusion period, rats were sacrificed. superoxide dismutase, catalase, nitric oxide, xanthine oxidase, malondialdehyde, protein carbonyl and myeloperoxidase levels were determined in hepatic tissue as well as histological examination with H and E staining. Group 3 animals demonstrated severe deterioration of liver morphology and a significant liver oxidative stress. Pretreatment of animals with leflunomide markedly attenuated morphological alterations and neutrophil activation, reduced elevated oxidative stress products levels and restored the depleted hepatic antioxidant enzyme. The findings imply that ROS play a causal role in I/R-induced hepatic injury, and leflunomide exerts hepatoprotective effects probably by the anti-inflammatory effect with radical scavenging and antioxidant activities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555109     DOI: 10.1007/s00383-006-1668-x

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  52 in total

1.  Can reperfusion injury of the liver be prevented? Trying to improve on a good thing.

Authors:  K M Olthoff
Journal:  Pediatr Transplant       Date:  2001-12

Review 2.  Mechanism and prevention of ischemia-reperfusion injury of the liver.

Authors:  T Kurokawa; T Nonami; A Harada; A Nakao; H Takagi
Journal:  Semin Surg Oncol       Date:  1996 May-Jun

Review 3.  Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.

Authors:  M L Herrmann; R Schleyerbach; B J Kirschbaum
Journal:  Immunopharmacology       Date:  2000-05

4.  A simple method for clinical assay of superoxide dismutase.

Authors:  Y Sun; L W Oberley; Y Li
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

Review 5.  Free-radical mechanisms in tissue injury.

Authors:  T F Slater
Journal:  Biochem J       Date:  1984-08-15       Impact factor: 3.857

6.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

Authors:  J S Beckman; T W Beckman; J Chen; P A Marshall; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis.

Authors:  S K Manna; A Mukhopadhyay; B B Aggarwal
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

8.  Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine.

Authors:  S Suzuki; L H Toledo-Pereyra; F J Rodriguez; D Cejalvo
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

Review 9.  Current progress in the understanding of and therapeutic strategies for ischemia and reperfusion injury of the liver.

Authors:  Shigeki Arii; Kennichi Teramoto; Toru Kawamura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

10.  Multiple-system organ damage resulting from prolonged hepatic inflow interruption.

Authors:  D L Liu; B Jeppsson; C H Hakansson; R Odselius
Journal:  Arch Surg       Date:  1996-04
View more
  14 in total

1.  Protection of Veratrum nigrum L. var. ussuriense Nakai alkaloids against ischemia-reperfusion injury of the rat liver.

Authors:  Zhen-Zhen Wang; Wei-Jie Zhao; Xue-Song Zhang; Xiao-Feng Tian; Yu-Zhu Wang; Feng Zhang; Jin-Chan Yuan; Guo-Zhu Han; Ke-Xin Liu; Ji-Hong Yao
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

2.  Hepatic damage in biliary-obstructed rats is ameliorated by leflunomide treatment.

Authors:  Abdurrahman Karaman; Mustafa Iraz; Hale Kirimlioglu; Nese Karadag; Erkan Tas; Ersin Fadillioglu
Journal:  Pediatr Surg Int       Date:  2006-08-05       Impact factor: 1.827

3.  Effect of leflunomide on liver regeneration after partial hepatectomy in rats.

Authors:  Abdurrahman Karaman; Hale Kirimlioglu; Erkan Tas; Nese Karadag; Cebrail Gülsul; Ersin Fadillioglu; Mehmet Demircan
Journal:  Pediatr Surg Int       Date:  2010-02       Impact factor: 1.827

4.  Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion.

Authors:  Yuksel Yildiz; Hayrullah Kose; Serpil Cecen; Kemal Ergin; Ece Mine Demir; Mukadder Serter
Journal:  Dig Dis Sci       Date:  2009-02-20       Impact factor: 3.199

5.  Phagocyte migration and cellular stress induced in liver, lung, and intestine during sleep loss and sleep recovery.

Authors:  Carol A Everson; Christa D Thalacker; Neil Hogg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-22       Impact factor: 3.619

6.  Does leflunomide attenuate the sepsis-induced acute lung injury?

Authors:  Erdogan Ozturk; Semra Demirbilek; Zekine Begec; Murat Surucu; Ersin Fadillioglu; Hale Kirimlioglu; M Ozcan Ersoy
Journal:  Pediatr Surg Int       Date:  2008-05-31       Impact factor: 1.827

7.  Sufentanil Protects the Liver from Ischemia/Reperfusion-Induced Inflammation and Apoptosis by Inhibiting ATF4-Induced TP53BP2 Expression.

Authors:  Ling Zhou; Xinlu Yang; Shuhua Shu; Sheng Wang; Fenglin Guo; Ying Yin; Weide Zhou; Han Han; Xiaoqing Chai
Journal:  Inflammation       Date:  2021-03-10       Impact factor: 4.092

8.  Doxorubicin induced nephrotoxicity: protective effect of nicotinamide.

Authors:  Sule Ayla; Ismail Seckin; Gamze Tanriverdi; Mujgan Cengiz; Mediha Eser; B C Soner; Gulperi Oktem
Journal:  Int J Cell Biol       Date:  2011-06-16

9.  Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation.

Authors:  Othman A Alshabanah; Mohamed M Hafez; Mohamed M Al-Harbi; Zeinab K Hassan; Salim S Al Rejaie; Yosef A Asiri; Mohamed M Sayed-Ahmed
Journal:  Oxid Med Cell Longev       Date:  2010-11-01       Impact factor: 6.543

10.  Therapeutic and protective effects of montelukast against doxorubicin-induced acute kidney damage in rats.

Authors:  Evren Köse; Fatih Oğuz; Nigar Vardi; Mehmet Ediz Sarihan; Ali Beytur; Aytaç Yücel; Alaadin Polat; Nihat Eki Nci
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.